专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009091720A3 N-linked glycosylation alteration in e1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine 审中-公开
标题翻译：的糖基化N IN CONNECTION糖蛋白E1 VIRUS猪瘟CLASSIC蚀变和疫苗对病毒
公开(公告)号：WO2009091720A3
公开(公告)日：2009-10-08
申请号：PCT/US2009030824
申请日：2009-01-13
申请人： US AGRICULTURE , BORCA MANUEL V , RISATTI GUILLERMO R
发明人： BORCA MANUEL V , RISATTI GUILLERMO R
IPC分类号： C12N15/33
CPC分类号： C07H21/04 , A61K39/12 , A61K2039/5254 , A61K2039/552 , C12N7/00 , C12N2770/24334 , C12N2770/24362 , G01N33/56983 , G01N2333/183
摘要： E1, along with Ems and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation. Infection of either E1. N1N2 or E1.N3 viruses were able to efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. These results, along with those demonstrating the role of glycosylation of Erps and E2, suggest that manipulation of the pattern of glycosylation could be a useful tool for development of CSF live-attenuated vaccines.
摘要翻译：根据本发明，E1，和E2用EMS，猪瘟（CSFV）的病毒的三个包膜糖蛋白中的一个。我们以往的研究表明，糖基化状态E2或Erns的强烈影响猪的病毒毒力。本发明是对病毒的高毒力株布雷西亚的E1糖基化的天然宿主的感染过程中的作用的研究结果。在E1的三个假定基化位点被CSFV布雷西亚（BICv）的感染性克隆的定点诱变来修饰。得到的一组突变体病毒的并用于确定在E1糖蛋白中除去推定的糖基化位点的改变是否在猪的毒力/病毒致病。据观察，在可行的拯救病毒完全被去除的E1三个假定基化位点改变。每个E1糖基化位N594的单突变表明CSFV氨基酸（E1.N3病毒），和N500和N513（E1.N1N2病毒）的组合突变导致衰减BICv。感染病毒或E1.N1N2 E1.N3，有效防止有毒BICv，3和感染28天后的猪。这些结果，与糖基化的Erns和E2的作用结果相结合表明，糖基化模式的操作是在减弱的猪瘟活疫苗发展的有用工具。

2. 发明申请

WO2009156448A1 ATTENUATED PESTIVIRUS 审中-公开
标题翻译：衰老的农药
公开(公告)号：WO2009156448A1
公开(公告)日：2009-12-30
申请号：PCT/EP2009/057911
申请日：2009-06-24
申请人： BOEHRINGER INGELHEIM VETMEDICA GMBH , MEYERS, Gregor , TEWS, Birke Andrea , SCHUERMANN, Eva-Maria
发明人： MEYERS, Gregor , TEWS, Birke Andrea , SCHUERMANN, Eva-Maria
IPC分类号： A61K39/12 , C07K14/18 , C12N7/04
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , C07K14/005 , C07K2319/50 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362
摘要： The present invention relates to recombinant attenuated pestivurses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric E ms glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well as to a method of attenuating a pestivirus comprising the step of modifying the E ms glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric E ms glycoprotein.
摘要翻译：本发明涉及重组减毒瘟病毒，特别是重组减毒CSFV，BVDV或BDV，其中所述重组减毒瘟病毒不产生二聚体Ems糖蛋白。本发明还涉及包含这种瘟病毒的免疫原性组合物以及减毒瘟病毒的方法，其包括通过缺失，插入或取代修饰Ems糖蛋白的步骤，其中这种修饰导致非二聚体Ems糖蛋白。

3. 发明申请

WO2004016794A1 REPLICONS OF PESTIVIRUSES THAT DO NOT EXPRESS C AND OR E1 PROTEIN AND INFECTIOUS VIRAL PARTICLES CONTAINING SAME, THAT CAN BE USED IN VACCINES 审中-公开
标题翻译：不能表达C和/或蛋白质的蛋白质和含有可能在疫苗中使用的感染性病毒颗粒的替代物
公开(公告)号：WO2004016794A1
公开(公告)日：2004-02-26
申请号：PCT/EP2003/009031
申请日：2003-08-12
申请人： AKZO NOBEL N.V. , BEER, Martin , REIMANN, Ilona
发明人： BEER, Martin , REIMANN, Ilona
IPC分类号： C12N15/86
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/552 , C07K14/005 , C12N15/86 , C12N2770/24322 , C12N2770/24343 , C12N2770/24362
摘要： The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be useful for vaccine purposes. The replicons encode most, preferably all, envelop proteins of the virus, while, on the other hand, it would not be capable of producing infectious progeny virus. The present invention provides a Pestiviral replicon, preferably from the Bovine Viral Diarrhea Virus (BVDV), which expresses all structural proteins except for a functional C or E1 protein. Preferably at least part of the coding sequence of the E1 or C protein has been deleted from said replicon. The present inventors proved for the first time, that both C and E1 structural proteins are essential for the formation of infectious pestiviruses. Furthermore it was shown that deletion of C and E1 does not impact the ability of RNA self-replication. By using cell lines constitutively expressing pestiviral structural proteins, Capsid- or E1-proteins can be efficiently trans -complemented. The resulting virions are able to infect bovine target cells and to transfer the replicons without generating replication-competent virus progeny. In other words, no infectious progeny virus is produced. The complemented virions are indistinguishable from wild-type Pestivirus.in virus neutralization experiments. Recombinations yielding infectious wild-type virus were not detected in any of the complementation experiments. The complemented viruses may be used for the safe and efficacious immunization against BVDV.
摘要翻译：本发明提供能够复制并且可以包装在补充缺失的蛋白质但不产生感染性后代病毒的细胞中的感染性病毒颗粒中的新的瘟病毒RNA基因组（复制子）。这样的复制子可以用于疫苗目的。复制子编码病毒的大多数，优选全部包膜蛋白，而另一方面，它将不能产生感染性后代病毒。本发明提供了一种优选来自牛病毒性腹泻病毒（BVDV）的Pestiviral复制子，其表达除功能性C或E1蛋白以外的所有结构蛋白。优选地，E1或C蛋白的编码序列的至少一部分已经从所述复制子中删除。本发明人首次证明了C和E1结构蛋白对于形成感染性瘟病毒是必不可少的。此外，显示C和E1的缺失不影响RNA自我复制的能力。通过使用组成型表达瘟病毒结构蛋白的细胞系，衣壳蛋白或E1蛋白可以有效地反式互补。所得到的病毒粒子能够感染牛靶细胞并转移复制子，而不产生具有复制能力的病毒后代。换句话说，没有产生感染性后代病毒。补充的病毒粒子与野生型瘟病毒在病毒中和实验中无法区分。在任何互补实验中未检测到产生感染性野生型病毒的重组。补充的病毒可用于对BVDV的安全有效的免疫。

4. 发明申请

WO0139801A2 SAFE ATTENUATED BOVINE VIRAL DIARRHEA VIRUSES FOR USE IN PREGNANT COWS 审中-公开
标题翻译：安全灭火牛病毒病毒病毒
公开(公告)号：WO0139801A2
公开(公告)日：2001-06-07
申请号：PCT/EP0011940
申请日：2000-11-29
申请人： BOEHRINGER INGELHEIM VETMED , MEYERS GREGOR , ELBERS KNUT
发明人： MEYERS GREGOR , ELBERS KNUT
IPC分类号： A61K39/12 , A61P31/12 , A61P31/14 , C07K7/04 , C07K14/18 , C12N7/04 , C12N15/40
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/544 , A61K2039/55 , A61K2039/552 , C12N7/00 , C12N2770/24322 , C12N2770/24334 , C12N2770/24361 , C12N2770/24362 , Y10S530/826
摘要： This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.
摘要翻译：本发明涉及特异性减毒的活BVD（牛病毒性腹泻）病毒用于制备用于预防和/或治疗牛，怀孕母牛育种中的BVDV感染的疫苗和在怀孕的母牛中用于胎儿保护的用途。

5. 发明申请

WO2015177369A1 RECOMBINANT CLASSICAL SWINE FEVER VIRUS (CSFV) COMPRISING SUBSTITUTION IN THE TAV EPITOPE OF THE E2 PROTEIN 审中-公开
标题翻译：在E2蛋白的TAV抗原中包含替代物的重组经典SWINE FEV病毒（CSFV）
公开(公告)号：WO2015177369A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/061473
申请日：2015-05-22
申请人： BOEHRINGER INGELHEIM VETMEDICA GMBH
发明人： MEYERS, Gregor , WIRTZ, Sabine
IPC分类号： C12N7/00 , A61K39/00 , A61K39/12
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/552 , C12N7/00 , C12N2770/24321 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362 , G01N33/56983 , G01N2333/185
摘要： The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.
摘要翻译：本发明涉及到涉及包含E2蛋白的氨基酸位置44的脯氨酸取代赖氨酸并在E2蛋白的氨基酸位置45将苏氨酸取代为天冬氨酸的CSFV（经典猪瘟病毒）。此外，本发明提供了包含本发明的CSFV的免疫原性组合物和免疫原性组合物用于降低与CSF相关的一种或多种临床体征的动物发生率或严重程度的用途。此外，本发明提供了用本发明的免疫原性组合物接种疫苗的动物区分感染了CSFV的动物的方法。

6. 发明申请

WO2012038454A1 BVDV VACCINE 审中-公开
公开(公告)号：WO2012038454A1
公开(公告)日：2012-03-29
申请号：PCT/EP2011/066377
申请日：2011-09-21
申请人： INTERVET INTERNATIONAL B.V. , BEER, Martin , REIMANN, Ilona , KOENIG, Patricia
发明人： BEER, Martin , REIMANN, Ilona , KOENIG, Patricia
IPC分类号： A61K39/295 , C07K14/18 , A61K39/12 , C12N7/00 , C12N7/04
CPC分类号： A61K39/12 , A61K39/295 , A61K39/40 , A61K39/42 , A61K2039/5254 , A61K2039/552 , A61K2039/70 , C07K14/005 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362
摘要： The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.
摘要翻译：本发明涉及BVD病毒及其用途，包含这种病毒的疫苗和组合疫苗，它们作为药物的用途，其用于治疗牛病毒性腹泻的用途以及用于制备这种疫苗的方法。

7. 发明申请

WO2010047955A3 N-linked glycosylation alteration in e0 and e2 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine 审中-公开
标题翻译：蚀变糖基化N联糖蛋白E0和E2病毒猪瘟旧版和新版病毒疫苗猪瘟CLASSIC
公开(公告)号：WO2010047955A3
公开(公告)日：2010-07-08
申请号：PCT/US2009059920
申请日：2009-10-08
申请人： US AGRICULTURE , BORCA MANUEL V , RISATTI GUILLERMO R
发明人： BORCA MANUEL V , RISATTI GUILLERMO R
IPC分类号： C12N15/33 , A61K39/12 , C12N7/00
CPC分类号： G01N33/56983 , A61K39/12 , A61K39/187 , A61K2039/5254 , A61K2039/543 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362 , C12Q1/701 , G01N2333/183
摘要： E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). E2 is involved in several functions including virus attachment and entry to target cells, production of antibodies, induction of protective immune response in swine, and virulence. Seven putative glycosylation sites in E2 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E2 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all putative glycosylation sites in E2, but restored when mutation N185A reverted to wild-type asparagine produced viable virus that was attenuated in swine. Single mutations of each of the E2 glycosylation sites showed that amino acid N1 16 (N 1 v virus) was responsible for BICv attenuation. N1 v efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection suggesting that glycosylation of E2 could be modified for development of CSF live-attenuated vaccines. Additionally, a new developed virus, contained deletions of putative glycosylation sites N1 in E2 and N 1 in EO (6b), called N1 E0/2v, induce a solid protection against the challenge at 3 and 28 days post-inoculation.
摘要翻译： E2是猪瘟（CSFV）的病毒的三个包膜糖蛋白之一。 E2参与多种功能，包括结合和进入病毒的靶细胞，抗体产生，在猪的保护性免疫应答的诱导，和毒力。在E2九月假定基化位点被CSFV布雷西亚（BICv）的感染性克隆的定点诱变来修饰。获得病毒突变体面板和用于研究在E2糖公认的糖基化位点的消除是否会影响猪的毒力/病毒致病。我们发现，可行的拯救病毒完全被去除E2所有公认的糖基化位点的改变，但恢复时在野生型天冬酰胺恢复N185A突变产生这是在猪减毒活病毒。每个E2糖基化位点的点突变证明，16 L1氨基酸（N1v病毒）负责BICv的衰减。 N1v有效保护猪抵抗暴露于致命的BICv 3和28天后感染，暗示E2糖基化可以为对抗CSF减毒活疫苗的研制进行修改。另外，含有E2和N1缺失N1假定基化位点在E0（6B）新开发的病毒，称为N1 E0 / 2体积诱导针对曝光一个牢固的保护，以3和28天接种后。

8. 发明申请

WO2015134480A1 A LIVE ATTENUATED ANTIGENICALLY MARKED CLASSICAL SWINE FEVER VACCINE 审中-公开
标题翻译：一个有力的抗衰老标签的经典的SWINE FEER VACCINE
公开(公告)号：WO2015134480A1
公开(公告)日：2015-09-11
申请号：PCT/US2015/018464
申请日：2015-03-03
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE , THE UNIVERSITY OF CONNECTICUT
发明人： BORCA, Manuel V. , RISATTI, Guillermo R. , HOLINKA-PATTERSON, Lauren G.
IPC分类号： C12N7/00 , C12N7/04 , C12N15/09 , A61K35/76
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/552 , C07K2319/40 , C07K2319/43 , C12N7/00 , C12N2770/24321 , C12N2770/24322 , C12N2770/24334 , C12N2770/24351 , C12N2770/24362 , C12N2770/24371 , G01N33/56983 , G01N2333/183
摘要： Controlling Classical Swine Fever Virus (CSFV) involves either prophylactic vaccination or non-vaccination and elimination of infected herds depending on the epidemiological situation. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement "stamping out" measures. Previously, we reported the development of FlagT4v, a double antigenic marker live attenuated CSFV strain. FlagT4v was later shown as not to be completely stable in terms of its attenuation when assessed in a reversion to virulence protocol. We have developed a modified version of the FlagT4v where changes in the codon usage of genomic areas encoding for Flag and T4 were introduced to rectify the reversion to the virulent genotype. The new virus, FlagT4-mFT-Gv, possesses the same amino acid sequence as FlagT4v except for one substitution, Asparagine is replaced by Glycine at position 852 of the CSFV polypeptide. FlagT4-mFT-Gv protected swine against challenge with Brescia virulent virus at 21 days post vaccination.
摘要翻译：控制经典猪热病毒（CSFV）涉及预防性接种疫苗或非疫苗接种，并根据流行病学情况消除感染的畜群。允许区分接种猪的天然感染的标记疫苗可以补充“冲洗”措施。以前，我们报道了FlagT4v的发展，FlagT4v是一种双抗原标志物活减毒CSFV毒株。 FlagT4v后来被证明在评估为毒力方案的逆转时，其衰减方面不能完全稳定。我们已经开发了FlagT4v的修改版本，其中引入了编码Flag和T4的基因组区域的密码子使用的变化来纠正到毒性基因型的逆转。新病毒FlagT4-mFT-Gv具有与FlagT4v相同的氨基酸序列，除了一个取代之外，天冬酰胺被CSFV多肽的852位的甘氨酸取代。 FlagT4-mFT-Gv在接种后21天保护猪免受布雷西亚毒性病毒攻击。

9. 发明申请

WO2010135054A2 MUTATIONS IN A TOLL-LIKE RECEPTOR MOTIF IN THE NS4B OF CLASSICAL SWINE FEVER VIRUS SKIN BRESCIA INFLUENCES VIRULENCE IN SWINE 审中-公开
标题翻译：经典蛇类病毒NS4B中类似感受态细胞的突变体病毒感染病毒感染SWA病毒
公开(公告)号：WO2010135054A2
公开(公告)日：2010-11-25
申请号：PCT/US2010/032151
申请日：2010-04-23
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE , BORCA, Manuel, V. , ZHU, James, J.
发明人： BORCA, Manuel, V. , ZHU, James, J.
IPC分类号： C12N15/40 , C12N15/63 , C12N7/01 , C07K14/08 , A61K39/12
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362
摘要： NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a motif that resembles those found in the toll-like receptor (TLR) proteins, a group of host cell proteins involved in the development of anti-viral mechanisms. We have located the TLR motif in two groups of amino acid triplets at amino acid positions 2531 -3 (residues IYK) and 2566-8 (residues VGI) of the CSFV NS4B glycoprotein. We have constructed a recombinant CSFV (derived from an infectious clone containing the genetic information of the highly virulent strain Brescia) containing amino acid substitutions in the three amino acid residues at positions 2566, 2567 and 2568, where the VGI triplet has been replaced by an AAA triplet inside the NS4B glycoprotein. The obtained virus, named NS4B-VGIv, was completely attenuated in swine, showing a limited ability in spreading during the infection in vivo . Although attenuated, NS4B-VGIv efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection.
摘要翻译： NS4B是经典猪瘟病毒的非结构蛋白之一。通过使用功能遗传学，我们已经发现，在CSFV菌株Brescia的NS4B的预测氨基酸序列中，类似于在toll样受体（TLR）蛋白中发现的基序，一组参与发展的宿主细胞蛋白抗病毒机制。我们将TLR基序定位在CSFV NS4B糖蛋白的氨基酸位置2531-3（残基IYK）和2566-8（残基VGI）的两组氨基酸三联体中。我们已经构建了重组CSFV（源自含有高毒力菌株Brescia的遗传信息的感染性克隆），其含有位置2566,2567和2568的三个氨基酸残基中的氨基酸取代，其中VGI三联体被 NS4B糖蛋白内的AAA三联体。获得的病毒NS4B-VGIv在猪中完全衰减，在体内感染期间展开的能力有限。尽管减毒，NS4B-VGIv在感染后3和28天有效地保护猪免受有毒BICv的攻击。

10. 发明申请

WO2010047955A2 N-LINKED GLYCOSYLATION ALTERATION IN E0 AND E2 GLYCOPROTEIN OF CLASSICAL SWINE FEVER VIRUS AND NOVEL CLASSICAL SWINE FEVER VIRUS VACCINE 审中-公开
标题翻译：经典猪发热病毒和新型经典猪发疹病毒E0和E2糖蛋白中N-连接的糖基化修饰
公开(公告)号：WO2010047955A2
公开(公告)日：2010-04-29
申请号：PCT/US2009/059920
申请日：2009-10-08
申请人： THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF AGRICULTURE , BORCA, Manuel, V. , RISATTI, Guillermo, R.
发明人： BORCA, Manuel, V. , RISATTI, Guillermo, R.
IPC分类号： C12N15/33 , C12N7/00 , A61K39/12
CPC分类号： G01N33/56983 , A61K39/12 , A61K39/187 , A61K2039/5254 , A61K2039/543 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362 , C12Q1/701 , G01N2333/183
摘要： E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). E2 is involved in several functions including virus attachment and entry to target cells, production of antibodies, induction of protective immune response in swine, and virulence. Seven putative glycosylation sites in E2 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E2 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all putative glycosylation sites in E2, but restored when mutation N185A reverted to wild-type asparagine produced viable virus that was attenuated in swine. Single mutations of each of the E2 glycosylation sites showed that amino acid N1 16 (N 1 v virus) was responsible for BICv attenuation. N1 v efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection suggesting that glycosylation of E2 could be modified for development of CSF live-attenuated vaccines. Additionally, a new developed virus, contained deletions of putative glycosylation sites N1 in E2 and N 1 in EO (6b), called N1 E0/2v, induce a solid protection against the challenge at 3 and 28 days post-inoculation.
摘要翻译： E2是经典猪瘟病毒（CSFV）的三种包膜糖蛋白中的一种。 E2涉及几种功能，包括病毒附着和进入靶细胞，产生抗体，诱导猪的保护性免疫应答和毒力。 E2中7个推定的糖基化位点通过CSFV Brescia感染性克隆（BICv）的定点诱变进行修饰。获得一组病毒突变体并用于研究E2糖蛋白中推定的糖基化位点的去除是否会影响猪的病毒毒力/发病机制。我们观察到拯救存活病毒完全受到E2中所有推定的糖基化位点的去除的损害，但当突变N185A恢复为野生型天冬酰胺产生在猪中减毒的活的病毒时恢复。每个E2糖基化位点的单个突变显示氨基酸N116（N1v病毒）负责BICv的减毒。 N1 v在感染后第3天和第28天有效保护了猪免于攻击强毒BICv，这表明可以修改E2的糖基化以开发CSF活减毒疫苗。此外，一种新开发的病毒，包含E2中假定的糖基化位点N1和EO（6b）中的N 1缺失，称为N1 E0 / 2v，在接种后第3天和第28天诱导针对攻击的固体保护。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式